Literature DB >> 19406050

[The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-small cell lung cancer patients. Initial results].

A Sánchez Salmón1, M Garrido, I Abdulkader, F Gude, L León, A Ruibal.   

Abstract

AIM: to study the expression of cyclin B1 and its possible relationship with the maximum SUV in FDG-PET and MIB1 expression in patients with NSCLC.
MATERIALS AND METHODS: 49 patients (15 adenocarcinomas, 27 squamous cell carcinomas and 7 bronchoalveolar carcinomas) were included in this study; the immunohistochemical expression of cyclin B1 was determined using the tissue-array technique. Each PET was performed 60 minutes after the i.v. administration of 350-518 MBq of FDG on an Advance system (GE) in 2D acquisition mode.
RESULTS: cyclin B1 expression was detected in 40 out of 45 cases. The SUV values were higher (p=0.04) in the cyclin B1+ cases than in the negative cases (16.4+/-8.1 vs 10.9+/-6.2). Cyclin B1 expression and SUV values were not correlated with the clinical stage. The expression of cyclin B1+ correlated positively (p<0.0001) with that of MIB1. After univariate analysis, only the cellular proliferation was a prognostic factor (p=0.037).
CONCLUSIONS: our results suggest that there is a direct correlation between cyclin B1 expression and max-SUV values in the PET of NSCLC patients. When the association of cyclin B1 with positive MIB1 is also considered, our results support the role of cell proliferation in FDG uptake by the tumour.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406050

Source DB:  PubMed          Journal:  Rev Esp Med Nucl        ISSN: 0212-6982


  2 in total

1.  Impact of cell-proliferation-associated gene expression on 2-deoxy-2-[(18)f]fluoro-D-glucose (FDG) kinetics as measured by dynamic positron emission tomography (dPET) in colorectal tumors.

Authors:  Ludwig G Strauss; Dirk Koczan; Sven Klippel; Leyun Pan; Caixia Cheng; Uwe Haberkorn; Stefan Willis; Antonia Dimitrakopoulou-Strauss
Journal:  Mol Imaging Biol       Date:  2010-12-10       Impact factor: 3.488

2.  Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.

Authors:  G P Ralli; R D Carter; F M Buffa; J D Fenwick; D R McGowan; W-C Cheng; D Liu; E J Teoh; N Patel; F Gleeson; A L Harris; S R Lord
Journal:  Breast Cancer Res       Date:  2022-05-17       Impact factor: 8.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.